Blue Cell Therapeutics ApS - CVR: 39981610

2022, DKK

19.06.2023

Bruttoresultat

852'

Primær drift

-14.800'

Årets resultat

-12.570'

Aktiver

10.625'

Kortfristede aktiver

10.192'

Egenkapital

9.911'

Afkastningsgrad

-139 %

Soliditetsgrad

93 %

Likviditetsgrad

+500%

Resultat

19.06.2023

Årsrapport	2022 19.06.2023	2021 21.06.2022	2020 21.07.2021	2018 08.09.2020
Nettoomsætning
Bruttoresultat	852.135	-843.696	-2.943.601	0
Resultat af primær drift	-14.800.129	-15.381.972	-14.950.828	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0
Finansielle indtægter	0	0	0	0
Finansieringsomkostninger	-64.462	-51.455	-41.071	0
Andre finansielle omkostninger	0	0	0	0
Resultat før skat	-14.864.591	-15.433.427	-14.991.899	0
Resultat	-12.569.961	-14.241.408	-14.026.899	0
Forslag til udbytte	0	0	0	0

Aktiver

19.06.2023

Årsrapport	2022 19.06.2023	2021 21.06.2022	2020 21.07.2021	2018 08.09.2020
Kortfristede varebeholdninger	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	6.186.997	2.739.617	3.758.541	2.000
Likvider	4.005.382	10.606.823	9.745.554	0
Kortfristede aktiver	10.192.379	13.346.440	13.504.095	2.000
Immaterielle aktiver og goodwill	0	0	0	0
Finansielle anlægsaktiver	103.800	56.238	0	0
Materielle aktiver	328.482	602.063	0	0
Langfristede aktiver	432.282	658.301	0	0
Aktiver	10.624.661	14.004.741	13.504.095	2.000

Aktiver

19.06.2023

Passiver

19.06.2023

Årsrapport	2022 19.06.2023	2021 21.06.2022	2020 21.07.2021	2018 08.09.2020
Forslag til udbytte	0	0	0	0
Egenkapital	9.911.253	12.481.214	9.775.822	2.000
Hensatte forpligtelser	0	0	0	0
Langfristet gæld til banker	0	0	0	0
Anden langfristet gæld	0	0	0	0
Leverandører af varer og tjenesteydelser	327.893	885.332	963.396	0
Kortfristede forpligtelser	713.408	1.523.527	3.728.273	0
Gældsforpligtelser	713.408	1.523.527	3.728.273	0
Forpligtelser	713.408	1.523.527	3.728.273	0
Passiver	10.624.661	14.004.741	13.504.095	2.000

Passiver

19.06.2023

Nøgletal

19.06.2023

Årsrapport	2022 19.06.2023	2021 21.06.2022	2020 21.07.2021	2018 08.09.2020
Afkastningsgrad	-139,3 %	-109,8 %	-110,7 %	Na.
Dækningsgrad	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-126,8 %	-114,1 %	-143,5 %	Na.
Payout-ratio	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-22.959,5 %	-29.894,0 %	-36.402,4 %	Na.
Soliditestgrad	93,3 %	89,1 %	72,4 %	100,0 %
Likviditetsgrad	1.428,7 %	876,0 %	362,2 %	Na.

Resultat

19.06.2023

Gæld

19.06.2023

Årsrapport

19.06.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 19.06.2023)

Information om virksomhedens regnskabsklasse:The annual report for Blue Cell Therapeutics ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises. The accounting policies are unchanged from last year, and the annual report is presented in DKK.

Beretning

19.06.2023

Dato for ledelsens godkendelse af årsrapporten:2023-05-16

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the board of directors and the managing director have presented the annual report of Blue Cell Therapeutics ApS for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Description of key activities of the company The principal activities of the company are to develop novel stem cell therapies to treat chronic diseases including erectile dysfunction. There is a large unmet clinical need for stem cell treatment of chronic diseases, however stem cell populations including Adipose Derived Regenerative Cells (ADRCs) are heterogenous and our understanding of their in vivo origin and properties is incomplete. Stem cell treatments hold the promise of modifying or even curing diseases, however the current regulatory environment need strong data for approval. In previous academic phase 1 trials, we have found that a single injection of the patients own ADRCs reversed erectile dysfunction in men. We have achieved a scientific breakthrough, and now have a new method for cell culturing of ADRC’s, so we can get more than 100. 000 doses from one donor. In addition, we are filing a new patent to protect this method. We are now ready for producing these cells at GMP conditions (Good Methodological Practice), transfer them from 2D to 3D culture, collect the required quality control data, perform a toxicology study in rodents and apply for permission to perform a regulatory phase I/II trial with our cultured lead cells. Our mission is to translate knowledge from basic science and animal experiments into novel treatments for chronic diseases including erectile dysfunction using our cultured stem cells with angiogenic and regenerative properties. Our goal is to introduce Blue Cell treatment for Erectile Dysfunction (ED) as the gold standard in hospitals and clinics to make the treatments available to patients worldwide. We have taken a large step towards delivering an ’overthe-counter’ stem cell therapy product for erectile dysfunction.